Pharmaceutical Executive September 27, 2021

Biotech company Ocugen got its start developing gene therapies for various forms of blindness diseases. Its breakthrough modifier gene therapy platform has the potential to address many rare retinal diseases with one product as well as address complex diseases that affect millions of people. Its novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy.

In late 2020, the company expanded to address the COVID-19 pandemic by partnering with Indian drug manufacturer, Bharat Biotech.

Dr. Shankar Musunuri is chairman, CEO, and co-founder of Ocugen. Prior to co-founding the company in 2013, Dr. Musunuri held leadership roles at numerous companies ranging from big pharma to...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Healthcare System, Interview / Q&A, Pharma / Biotech, Public Health / COVID, Trends
Brazil’s plan for low-cost CAR-Ts
PacBio’s Repeat Expansion Panel, Owkin-Sanofi AI Take on Immunology, More
STAT+: Borrowing an idea from cancer immunotherapy, scientists make old-mice immune systems youthful again
Moderna gets Blackstone backing for flu vaccine R&D
FDA Approves Winrevair, Merck’s Novel Treatment for Pulmonary Arterial Hypertension

Share This Article